Therefore, by blocking VEGF-VEGFR pathway, bevacizumab is able to restore the immune adaptive mechanisms of the tumour microenvironment, enhancing T-cell priming and activation via promotion of DCs maturation, increasing effector T-cells tumour infiltration by normalising tumour vasculature, and establishing an immune-permissive tumour microenvironment by reducing level of Treg and tumour-associated MDSC populations [24–27]. Here, KDR is linked to neoplasm.